This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Covell, D. G. Articles by Weinstein, J. N. Search for Related Content PubMed PubMed Citation Articles by Covell, D. G. Articles by Weinstein, J. N.

Pharmacokinetics of Monoclonal Immunoglobulin G₁, F(ab')₂, and Fab' in Mice

Laboratory of Mathematical Biology [D. G. C., J. B., O. D. H., C. D. V. B., J. N. W.] and Office of the Chief, Division of Cancer Etiology [R. J. P.], National Cancer Institute, NIH, Bethesda, Maryland 20892

The pharmacokinetics of an immunoglobulin G1 (IgG1) and its F(ab')₂ and Fab' fragments following i.v. administration in mice has been studied by constructing a physiologically based, organ-specific model to describe antibody biodistribution, catabolism, and excretion. The antibody selected for study (MOPC-21) has no known binding sites in the body and therefore is useful for defining antibody metabolism by nontumor tissues. Whole IgG (a) remains in the body for 8.3 days, the majority of time in the carcass (53.0% of the total residence time); (b) has a distribution volume exceeding that of plasma plus interstitial fluid; (c) distributes into these volumes rapidly for most enteral organs (equilibration time <2.6 min for liver, spleen, kidney, and lung), slower for the gut (<20 min), and slowest for carcass (<260 min); (d) produces interstitial:plasma concentration ratios of >0.5 for enteral organs and 0.18 for carcass; (e) has the greatest percentage of its catabolism due to the gut (72.8%), followed by the liver (20.5%), then the spleen (3.6%); (f) has the highest extraction on a single pass by the gut (0.14%) and (g) cycles through the interstitial spaces of the body at least 2.8 times/g of organ weight before being metabolized or excreted. When compared with whole IgG, the Fab' fragment (a) is cleared from the body 35 times faster; (b) has a larger total distribution volume; (c) distributes more rapidly into this volume; (d) produces higher interstitial:plasma concentration ratios; (e) is catabolized principally by the kidney (73.4% of total catabolism), followed by the gut (22.9%), then the spleen (3.1%); (f) is extracted from the circulation to the extent of 3.4% on each pass through the kidney, and less by gut (1.0%) and spleen (0.14%) and (g) cycles through non-kidney interstitial spaces at least 0.4 cycles/g of tissue weight before metabolism or excretion. The F(ab')₂ fragment has pharmacokinetic characteristics that fall between those of whole IgG and Fab'. These results (a) provide pharmacokinetic criteria for selecting whole IgG, F(ab')₂, or Fab' for various in vivo applications; (b) provide a framework for predicting cumulative tissue exposure to antibody labeled with different isotopes; and (c) provide a reference metabolic state for the analysis of more complex systems that do include antibody binding.

Received 2/12/86. Revised 4/30/86. Accepted 5/ 6/86.

This article has been cited by other articles:

				M. E. Ackerman, D. Pawlowski, and K. D. Wittrup Effect of antigen turnover rate and expression level on antibody penetration into tumor spheroids Mol. Cancer Ther., July 1, 2008; 7(7): 2233 - 2240. [Abstract] [Full Text] [PDF]

				D. P. Humphreys, S. P. Heywood, A. Henry, L. Ait-Lhadj, P. Antoniw, R. Palframan, K. J. Greenslade, B. Carrington, D. G. Reeks, L. C. Bowering, et al. Alternative antibody Fab' fragment PEGylation strategies: combination of strong reducing agents, disruption of the interchain disulphide bond and disulphide engineering Protein Eng. Des. Sel., May 1, 2007; 20(5): 227 - 234. [Abstract] [Full Text] [PDF]

				H. Farhan, C. Schuster, M. Klinger, E. Weisz, G. Waxenecker, M. Schuster, V. Sexl, G. C. Mudde, M. Freissmuth, and R. Kircheis Inhibition of Xenograft Tumor Growth and Down-Regulation of ErbB Receptors by an Antibody Directed against Lewis Y Antigen J. Pharmacol. Exp. Ther., December 1, 2006; 319(3): 1459 - 1466. [Abstract] [Full Text] [PDF]

				G. Z. Ferl, V. Kenanova, A. M. Wu, and J. J. DiStefano III A two-tiered physiologically based model for dually labeled single-chain Fv-Fc antibody fragments. Mol. Cancer Ther., June 1, 2006; 5(6): 1550 - 1558. [Abstract] [Full Text] [PDF]

				D. Kamimura, N. Ueda, Y. Sawa, S. Hachida, T. Atsumi, T. Nakagawa, S.-i. Sawa, G.-H. Jin, H. Suzuki, K. Ishihara, et al. Evidence of a Novel IL-2/15R{beta}-Targeted Cytokine Involved in Homeostatic Proliferation of Memory CD8+ T Cells J. Immunol., November 15, 2004; 173(10): 6041 - 6049. [Abstract] [Full Text] [PDF]

				G. Hong, M. Bazin-Redureau, P. Gires, and J. M. Scherrmann Hepatic Disposition and Toxicity of Cationized Goat Immunoglobulin G and Fab Fragments in Isolated Perfused Rat Liver Drug Metab. Dispos., July 1, 1998; 26(7): 661 - 669. [Abstract] [Full Text]